Entrepreneurs and investors who have participated in financing rounds of the life sciences and health sector will meet at the Barcelona Science Park to discuss the assessment of biotechnology and biomedical companies.
The pre-money valuation of a biotech company in its early stages has a direct impact on the dilution of the participation of entrepreneurs and the future return for investors. However, often the future consequences of a too high or too low valuation are not considerated.
What factors are involved in the assessment of a biotechnology company in the early stages? How can an entrepreneur negotiate a satisfactory assessment? We will discuss all these aspects and others that arise during the debate and will try not to stay in the general concepts but go into greater detail with concrete examples.
MODERATOR: Jordi Naval, General Director, Fundació Bosch i Gimpera
Carles Domènech, CEO, Ability Pharmaceuticals, SL
Jordi Carrera, CEO, STAT-Diagnostica & Innovation
Daniel Oliver, Director, Capital Cell
Alain Garcinuño, CFO, Anaconda BioMed
Lluís Pareras, Director, Healthequity, SCR
The sessions Lessons Learned: Sharing experiences to boost competitiveness are a knowledge and networking forum geared towards professionals from companies in the life sciences arena. They aim to allow participants to share their experience and reflections in various strategic areas of knowledge and the skills needed to boost competitiveness in biotechnology companies.